Antibiotic Adverse Reactions and Drug Interactions

Critical Care Clinics

Volumn 24, Issue 2, 2008, Pages 421-442

  Granowitz, Eric V ^a   Brown, Richard B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ECHINOCANDIN; ERYTHROMYCIN; FLUCYTOSINE; GANCICLOVIR; GLYCOPEPTIDE; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; MONOBACTAM DERIVATIVE; NITROFURANTOIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMYCIN; STREPTOGRAMIN; TETRACYCLINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANEMIA; ANTIBIOTIC THERAPY; BLOOD CLOTTING DISORDER; CARDIOTOXICITY; DIARRHEA; DRUG HYPERSENSITIVITY; ELECTROLYTE DISTURBANCE; FEVER; HALLUCINATION; HEARING LOSS; HUMAN; INTENSIVE CARE; LEUKOPENIA; LIVER TOXICITY; MUSCLE TWITCH; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; VERTIGO;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; HUMANS; INTENSIVE CARE UNITS; SEVERITY OF ILLNESS INDEX;

EID: 40849092543     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2007.12.011     Document Type: Review

References (117)

1. Lazarou J., Pomeranz B.H., and Corey P.H. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
2. Faulkner C.M., Cox H.L., and Williamson J.C. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 40 (2005) 997-1004
3. Pirmohamed M., and Park B.K. HIV and drug allergy. Curr Opin Allergy Clin Immunol 1 (2001) 311-316
4. Roder B.L., Nielsen S.L., Magnussen P., et al. Antibiotic usage in an intensive care unit in a Danish university hospital. J Antimicrob Chemother 32 (1993) 633-642
5. Vincent J.L., Bihari D.J., Suter P.M., et al. The prevalence of nosocomial infections in intensive care units in Europe. JAMA 274 (1995) 639-644
6. Idsoe O., Guthe T., Wilcox R.R., et al. Nature and extent of penicillin side-reactions with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 38 (1968) 159-188
7. Saxon A., Beall G.N., Rohr A.S., et al. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 107 (1987) 204-215
8. Salkind A.R., Cuddy P.G., and Foxworth J.W. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 19 (2001) 2498-2505
9. Park M.A., and Li J.T.C. Diagnosis and management of penicillin allergy. Mayo Clin Proc 80 (2005) 405-410
10. Kelkar P.S., and Li J.T.C. Cephalosporin allergy. N Engl J Med 345 (2001) 804-809
11. Apter A.J., Kinman J.L., Bilker W.B., et al. Is there cross-reactivity between penicillins and cephalosporins?. Am J Med 119 (2006) 354.e11-354.e20
12. Saxon A., Adelman D.C., Patel A., et al. Imipenem cross-reactivity with penicillin in humans. J Allergy Clin Immunol 82 (1988) 213-217
13. Prescott Jr. W.A., DePestel D.D., Ellis J.J., et al. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis 38 (2004) 1102-1107
14. Romano A., Viola M., Gueant-Rodriguez R.M., et al. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 354 (2006) 2835-2837
15. Romano A., Viola M., Gueant-Rodriguez R.M., et al. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med 146 (2007) 266-269
16. Kao L.W., and Furbee R.B. Drug-induced Q-T prolongation. Med Clin North Am 89 (2005) 1125-1144
17. Ray W.A., Murray K.T., Meredith S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351 (2004) 1089-1096
18. Glicklich D., and Figura I. Vancomycin and cardiac arrest. Ann Intern Med 101 (1984) 880-881
19. Southorn P.A., Plevak D.J., Wright A.J., et al. Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc 61 (1986) 721-724
20. Clements J.S., and Peacock J.E. Amphotericin B revisited: reassessment of nephrotoxicity. Am J Med 88 (1990) 22N-27N
21. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients. A multinational, multicenter study. JAMA 294 (2005) 813-818
22. Smith C.R., Lipsky J.J., Laskin O.L., et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302 (1980) 1106-1109
23. Matzke G.R., Lucarotti R.L., and Shapiro H.S. Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol 3 (1983) 11-17
24. Sawyers C.L., Moore R.D., Lerner S.A., et al. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 153 (1986) 1062-1068
25. Hatala R., Dinh T., and Cook D.J. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 124 (1996) 717-725
26. Barza M., Ioannidis J.P., and Capelleri J.C. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312 (1996) 338-344
27. Gallis H.A., Drew R.H., and Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12 (1990) 308-329
28. Takacs F.J., Tomkiewicz Z.M., and Merrill J.P. Amphotericin B nephrotoxicity with irreversible renal failure. Arch Intern Med 59 (1963) 716-724
29. Fisher M.A., Talbot G.H., Maislin G., et al. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 87 (1989) 547-552
30. Heidemann H.T., Gerkens J.F., Spickard W.A., et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 75 (1983) 476-481
31. Baldwin D.S., Levine B.B., McCluskey R.T., et al. Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med 279 (1968) 1245-1252
32. Alexopoulos E. Drug-induced acute interstitial nephritis. Ren Fail 20 (1998) 809-819
33. Green S.L., Maddox J.C., and Huttenbach E.D. Linezolid and reversible myelosuppression. JAMA 285 (2001) 1291
34. Birmingham M.C., Rayner C.R., Meagher A.K., et al. Linezolid for the treatment of multidrug resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
35. Bernstein W.B., Trotta R.F., Rector J.T., et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 37 (2003) 517-520
36. Wallerstein R.O., Condit P.K., Kasper C.K., et al. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 208 (1969) 2045-2050
37. Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia: a report from the International Agranulocytosis and Aplastic Anemia Study. Arch Intern Med 149 (1989) 1036-1040
38. Andres E., and Maloisel F. Antibiotic-induced agranulocytosis: a monocentric study of 21 cases. Arch Intern Med 161 (2001) 2610
39. Neftel K.A., Hauser S.P., and Muller M.R. Inhibition of granulopoiesis in vivo and in vitro by β-lactam antibiotics. J Infect Dis 152 (1985) 90-98
40. Bang N.U., and Kammer R.B. Hematologic complications associated with β-lactam antibiotics. Rev Infect Dis 5 (1983) S380-S393
41. Olaison L., Belin L., Hogevik H., et al. Incidence of β-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med 159 (1999) 607-615
42. Singh N., Yu V.L., Mieles L.A., et al. β-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing patients with liver disease. Am J Med 94 (1993) 251-256
43. Kesarwala H.H., Rahill W.J., and Amaram N. Vancomycin-induced neutropenia. Lancet 1 (1981) 1423
44. Brown R.B., Sands M., and Ryczak M. Antibiotics and bleeding. Infect Med 4 (1987) 386-392
45. Von Drygalski A., Curtis B.R., Bougie D.W., et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 356 (2007) 904-910
46. Aster R.H., and Bougie D.W. Drug-induced immune thrombocytopenia. N Engl J Med 357 (2007) 580-587
47. Brown R.B., Klar J., Teres D., et al. Prospective study of clinical bleeding in intensive care unit patients. Crit Care Med 16 (1988) 1171-1176
48. Brown R.B., Klar J., Lemeshow S., et al. Enhanced bleeding with cefoxitin or moxalactam: statistical analysis within a defined population of 1493 patients. Arch Intern Med 146 (1986) 2159-2164
49. Fass R.J., Copelan E.A., Brandt J.T., et al. Platelet-induced bleeding caused by broad-spectrum antibiotics. J Infect Dis 155 (1987) 1242-1248
50. Malpass T.W., and Harker L.A. Acquired disorders of platelet function. Semin Hematol 17 (1980) 242-258
51. Shevchuk Y.M., and Conly J.M. Antibiotic-associated hypoprothrombinemia: a review of prospective studies 1966-1988. Rev Infect Dis 6 (1990) 1109-1126
52. Kline S.S., Mauro V.F., Forney R.B., et al. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. Antimicrob Agents Chemother 31 (1987) 1328-1331
53. Lipsky J.J. N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinemia. Lancet 2 (1983) 192-193
54. Fonacier L., Hirschberg R., and Gerson S. Adverse drug reactions to cephalosporins in hospitalized patients with a history of penicillin allergy. Allergy Asthma Proc 26 (2005) 135-141
55. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285
56. Wallace M.R., Mascola J.R., and Oldfield III E.C. Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis 164 (1991) 1180-1185
57. O'Sullivan T.L., Ruffing M.J., Lamp K.C., et al. Prospective evaluation of red man syndrome in patients receiving vancomycin. J Infect Dis 168 (1993) 773-776
58. Polk R.E., Healy D.P., Schwartz L.B., et al. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis 157 (1988) 502-507
59. Sahai J., Healy D.P., Garris R., et al. Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome. J Infect Dis 160 (1989) 876-881
60. Fausti S.A., Henry J.A., Schaffer H.I., et al. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 165 (1992) 1026-1032
61. Swanson D.J., Sung R.F., Fine M.J., et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 92 (1992) 61-69
62. Wallace M.R., Miller L.K., Nguyen M.T., et al. Ototoxicity with azithromycin. Lancet 343 (1994) 241
63. Ress B.D., and Gross E.M. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity: a case report. Ann Otol Rhinol Laryngol 109 (2000) 435-437
64. Umstead G.S., and Neumann K.H. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction. Arch Intern Med 146 (1986) 897-899
65. Moore R.D., Smith C.R., and Leitman P.S. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 149 (1984) 23-30
66. Gatell J.M., Ferran F., Araujo V., et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 31 (1987) 1383-1387
67. Fee Jr. W.E. Gentamicin and tobramycin: comparison of ototoxiciy. Rev Infect Dis 5 (1983) S304-S313
68. Farber B.F., and Moellering Jr. R.C. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23 (1983) 138-141
69. Cook F.V., and Farrar W.E. Vancomycin revisited. Arch Intern Med 88 (1978) 813-818
70. Snavely S.R., and Hodges G.R. The neurotoxicity of antibacterial agents. Arch Intern Med 101 (1984) 92-104
71. Eng R.H.K., Munsif A.N., Nangco B.G., et al. Seizure propensity with imipenem. Arch Intern Med 149 (1989) 1881-1883
72. Chow K.M., Hui A.C., and Szeto C.C. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 24 (2005) 649-653
73. Barza M. Imipenem: first of a new class of beta-lactam antibiotics. Ann Intern Med 103 (1985) 552-559
74. File T.M., and Tan J.S. Recommendations for using imipenem-cilastatin-the most broad spectrum antibiotic. Hosp Formul 22 (1987) 534-542
75. Owens R.C., and Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41 (2005) S144-S157
76. Brown S.J., and Desmond P.V. Hepatotoxicity of antimicrobial agents. Semin Liver Dis 22 (2002) 157-167
77. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N Engl J Med 354 (2006) 731-739
78. Park-Wyllie L.Y., Juurlink D.N., Kopp A., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354 (2006) 1352-1361
79. Cunha B.A., and Shea K.W. Fever in the intensive care unit. Infect Dis Clin North Am 10 (1996) 185-209
80. McGowan J.E., Rose R.C., Jacobs N.F., et al. Fever in hospitalized patients. Am J Med 82 (1987) 580-586
81. Arbo M.J., Fine M.J., Hanusa B.H., et al. Fever of nosocomial origin: etiology, risk factors, and outcomes. Am J Med 95 (1993) 505-512
82. DiNubile M.J. Acute fevers of unknown origin: a plea for restraint. Arch Intern Med 153 (1993) 2525-2526
83. Semel J.D. Fever associated with repeated intramuscular injections of analgesics. Rev Infect Dis 8 (1986) 68-72
84. Mellors J.W., Horwitz R.I., Harvey M.R., et al. A simple index to identify occult bacterial infection in adults with acute unexplained fever. Arch Intern Med 147 (1987) 666-671
85. Samore M.H., Degirolami P.C., Tlucko A., et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 18 (1994) 181-187
86. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145 (2006) 758-764
87. McFarland L.V., Mulligan M.E., Kwok R.Y.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989) 204-210
88. Wolf L.E., Gorbach S.L., and Granowitz E.V. Extraintestinal Clostridium difficile: 10 years' experience at a tertiary-care hospital. Mayo Clin Proc 73 (1998) 943-947
89. Wanahita A., Goldsmith E., Marino B.J., et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 115 (2003) 543-546
90. Triadafilopoulos G., and Hallstone A.E. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 101 (1991) 685-691
91. Manabe Y.C., Vinetz J.M., Moore R.C., et al. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 123 (1995) 835-840
92. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 92 (1997) 739-750
93. Zar F.A., Bakkanagari S.R., Moorthi K.M.L.S.T., et al. A comparision of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007) 302-307
94. Bolton R.P., and Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 (1986) 1169-1172
95. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis: diagnosis, antimicrobial therapy and management of complications. Circulation 111 (2005) 3167-3184
96. Le T., and Bayer A.S. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 36 (2003) 615-621
97. Korzeniowski O., and Sande M.A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts. Ann Intern Med 97 (1982) 496-503
98. Safdar N., Handelsman J., and Maki D.G. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet 4 (2004) 519-527
99. Kluge R.M., Standiford H.C., Tatem B., et al. Comparative activity of tobramycin, amikacin and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 6 (1974) 442-446
100. Comber K.R., Basker M.J., Osborne C.D., et al. Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother 11 (1977) 956-964
101. Yoshikawa T.T., and Shibata S.A. In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 13 (1978) 997-999
102. Archer G., and Fekety Jr. F.R. Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J Infect Dis 136 (1977) 327-335
103. Heineman H.S., and Lofton W.M. Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinatons in vitro. Antimicrob Agents Chemother 13 (1978) 827-831
104. Hilf M., Yu V.L., Sharp J., et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 87 (1989) 540-546
105. Chamot E., Bobbi El Amari E., Rohner P., et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47 (2003) 2756-2764
106. Micek S.T., Lloyd A.E., Ritchie D.J., et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 (2005) 1306-1311
107. Acar J.F. Antibiotic synergy and antagonism. Med Clin North Am 6 (2000) 1391-1406
108. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., et al. Combination antifungal therapy. Antimicrob Agents Chemother 48 (2004) 693-715
109. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 18 (2005) 163-194
110. Stevens D.L., Ma Y., Salmi D.B., et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195 (2007) 202-210
111. Cammu G. Interactions of neuromuscular blocking drugs. Acta Anaesthesiol Belg 52 (2001) 357-363
112. Pai M.P., Momary K.M., and Rodvold K.A. Antibiotic drug interactions. Med Clin North Am 90 (2006) 1223-1255
113. Finch C.K., Chrisman C.R., Baciewicz A.M., et al. Rifampin and rifabutin drug interactions. Arch Intern Med 162 (2002) 985-992
114. Lavery S.R., Ravi H., McDaniel W.W., et al. Linezolid and serotonin syndrome. Psychosomatics 42 (2001) 432-434
115. Gillman P.K. Linezolid and serotonin toxicity. Clin Infect Dis 37 (2003) 1274-1275
116. Lawrence K.R., Adra M., and Gillman P.K. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 42 (2006) 1578-1583
117. Taylor J.J., Wilson J.W., and Estes L.L. Linezolid and serotonergic drug interactions: a restrospective survey. Clin Infect Dis 43 (2006) 180-187